Highly selective and potent antiviral agents from the Riboscience Nucleoside Platform have the potential to cure broad-spectrum viral respiratory infections.
PROBLEM:
Influenza and Coronavirus pose pandemic threats—with new variants constantly emerging.
SOLUTION:
Nucleosides are broadly active across variants—potentially offering wider protection as viruses evolve.
PROBLEM:
Drug resistance is a constant challenge. Multiple classes of antiviral agents are required for pandemic preparedness.
SOLUTION:
Riboscience’s nucleosides have demonstrated a high barrier to resistance, with the potential to outperform traditional treatment options.